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Abstract
Background: With continuous increases in survival rates following breast cancer 
(BC) diagnosis, the challenge of multiple primary cancers has become an issue. The 
data on familial risk of SPCs after BC diagnosis and the related mortality in BC 
patients are scarce.
Methods: A total of 87 752 female BC patients were followed for SPC diagnoses 
and records of death. Relative risks (RRs) of SPC in BC patients who had first‐de-
gree relatives (parents or siblings) affected by the same cancer were compared to the 
patients without family history. Causes of death were compared between patients 
with and without SPC.
Results: After a median follow‐up of 5 years, 14 952 BC patients developed SPCs, 
among which 10 280 (68.8%) had first‐degree relatives diagnosed with cancer. 
Familial risks were significant for 14 site‐specific SPCs, and the highest risk was for 
second ovarian cancer (RR = 6.28, 95%CI: 4.50‐8.75), compared to those without 
family history (1.49, 1.34‐1.65). In patients with SPC, SPC was the main cause of 
death, including diverse cancers and BC in approximately equal proportions.
Conclusions: Family history contributed to the excess number of patients with SPCs, 
and SPC was the leading cause of death in patients with SPC. Taking family history 
at diagnosis of BC may provide warning signs with regard to possible subsequent 
SPCs and may offer possibilities for counseling, intervention and management.
K E Y W O R D S
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1 |  INTRODUCTION
Survival rates following cancer diagnosis have improved 
and increased the likelihood for multiple primary cancers.1,2 
Breast cancer (BC) is common, and survival is generally 
good resulting in multiple primary cancers diagnosed in 
many patients. In the Swedish and German cancer registries, 
second primary cancers (SPCs) after BC account respec-
tively for 11.8% and 10.9% of all SPCs.3 Known causes for 
multiple primary cancers in BC patients include radiother-
apy, chemotherapy, hormonal and genetic factors.1,2,4 High 
risks for contralateral BC are well known and associate 
with familial BC although many such patients lack a family 
history of BC.5 Gene mutations in BRCA1/2 constitute the 
dominant germline cause for heritable BC; these mutations 
are estimated to account for 1.4% of all BCs in European 
and African American populations.6 They also confer a high 
risk of ovarian cancer and a smaller but still increased risk 
of many other cancers.7 Although population‐level data on 
higher order multiple cancers (third, fourth etc primary can-
cers) should increase along with SPCs, they are often asso-
ciated with genetic predisposition in the context of cancer 
syndromes.1,4,8,9 In cancers featuring good survival, such as 
Hodgkin lymphoma and testicular cancer, SPCs are the main 
cause of death.1,10-13
Here we investigate risk for and mortality due to multiple 
primary cancers in BC patients. The resource used was the 
Swedish Family‐Cancer Database covering the Swedish pop-
ulation essentially through more than a century with linked 
cancers from the national cancer registry.
2 |  METHODS
Our Swedish Family‐Cancer Database was created by in-
corporating the Multigeneration Register, National Cancer 
Registry (started in 1958), national censuses and Cause of 
Death Register. This database includes all Swedish people 
born after 1931 (offspring generation) and their biologi-
cal parents (parental generation). The latest version of the 
Swedish Family‐Cancer Database contained 16.1 million 
individuals among which 2.0 million were cancer patients 
recorded to the end of 2015. The follow‐up for cancer in the 
offspring generation was started from the beginning of 1958, 
the birth year, or the immigration year, whichever came lat-
est. The follow‐up was terminated when a person was diag-
nosed with cancer, emigrated or died, or at the end of 2015, 
whichever came first. Follow‐up for SPC was started at diag-
nosis of first BC and terminated at diagnosis of SPC, emigra-
tion, death, or at the end of 2015.
Family history was defined through first‐degree relatives 
(parents or siblings). In situ cancers in breast, colorectum, 
melanoma and squamous cell (SCC) skin in family members 
were also included because familial risk in these in situ can-
cers are approximately equally as high as in invasive can-
cers.14 For the overall risk calculation, only family history 
of invasive cancers was considered. Cumulative incidence 
of SPC with or without a family history of concordant can-
cer was calculated considering death as a competing event. 
Poisson regression model was employed to estimate relative 
risks (RRs) and corresponding 95% confidence intervals 
(CIs) for SPC in the offspring generation by comparing the 
incidence of cancer as SPC in BC with or without family his-
tory to the incidence of the same cancer as a first primary can-
cer in general population of the database, which had neither 
a family history of SPC nor BC (except for risk estimation 
of second BC). Significance levels were indicated also for 
1% and 0.1%. Trend test was performed to compare RRs of 
SPC estimated from Poisson regression in patients who had 
first‐degree relatives affected by the same cancer (positive 
family history) to the patients without family history (neg-
ative family history). Potential confounders, including age 
group (5‐year bands), calendar period (5‐year bands), resi-
dential area (large cities, South Sweden, North Sweden, or 
unspecified) and socioeconomic status (blue‐collar worker, 
white‐collar worker, farmer, private, professional, or other/
unspecified) were added to the model as covariates. All the 
hypothesis tests were 2‐sided.
Underlying and contributing cause of death were ob-
tained from the Swedish Cause of Death Register and were 
recorded according to the WHO International Classification 
of Diseases (ICD‐7, 1961; ICD‐8, 1969‐1986; ICD‐9, 
1987‐1996; ICD‐10, 1997‐2015). All cancer related deaths 
were stratified into BC, SPC, higher order primary cancer 
and “other cancer”. In BC patients with second BC the cause 
of death was assigned to BC even though it was not known 
whether first or second BC killed the patient. Higher order 
primary cancer classification included patients who died of 
third, fourth or fifth primary cancer. “Other cancer” included 
cancers diagnosed at the issue of death certificates and they 
were not the first cancer, SPC or higher order primary cancer. 
These death certificate notifications are not counted by the 
Swedish Cancer Registry, opposite to the other Nordic Cancer 
Registries.15-17 Upon scrutiny of these cancers we found that 
they included often cancer of unknown primary (CUP). In 
our previous analyses these cancers have been interpreted as 
metastases.18,19 If the death certificate notification matched 
the organ site of the reported primary cancer, it was classi-
fied as BC but in most cases such an assignment could not be 
made and the classification was to “other cancer”. Other non‐
neoplastic causes of death were reported as “other cause”. 
Statistical analyses were done with SAS version 9.4.
The study was approved by the Ethical Committee of 
Lund University without requirement for informed consent, 
and the study was conducted in accordance with the approved 
guidelines.
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3 |  RESULTS
A total of 87 752 BC patients were identified in women in the 
offspring generation born after 1931 (Table 1), for whom the 
RRs were estimated in Table 2. The number of BC patients in 
the parental generation was 166 083. The median age at diag-
nosis of BC was 55 years. A total of 14 952 patients (17.0%) 
were diagnosed with SPC at the median age of 63 years, and 
for 8653 (57.9%) of them, SPC was BC. Among 8626 pa-
tients whose information was available, 42.1% were second 
BC in the same breast and 57.9% were contralateral. The 
median follow‐up time from diagnosis of first BC was only 
1 year to second BC whereas it was 8 years to other SPC. 
Among patients diagnosed with SPC, 68.8% had cancer fam-
ily history. In familial SPC, 2228 (21.6%) SPCs were the 
same (concordant) cancer that was diagnosed in the family 
members, and for 8052 (77.4%) patients it was a discordant 
familial cancer. Among the patients with SPCs, 2543 (17.0%) 
were diagnosed with third primary cancers. A total of 18 998 
(21.6%) death cases were observed in BC patients, 4828 of 
which had SPC diagnoses (fatality rate of 32.3% in BC with 
SPC). For patients with SPCs with and without family his-
tory the overall fatality rate was equal, 32.6% and 31.5%, re-
spectively. However, the fatality rate for the patients without 
SPCs (16.1%) was half of that for the patients with SPCs.
The impact of family history on the risk of SPCs was as-
sessed in Table 2. An increased risk for SPC was found in BC 
patients, who had a first‐degree relative diagnosed with any 
cancer (RR, 3.54, 95%CI, 3.46‐3.62) compared to patients 
without family history (3.00, 2.91‐3.09). When only con-
sidering SPCs other than BC, the respective RRs were 1.53 
(1.49‐1.58) and 1.25 (1.19‐1.31), translating to an attributable 
risk proportion of 18.3% ((1.53‐1.25) /1.53) for family history 
of cancer. For site‐specific cancer, the trend tests were signif-
icant for 14 SPCs (See Table 2). The highest risk for second 
malignancy was shown for ovarian cancer (6.28, 4.50‐8.75 
with family history vs 1.49, 1.34‐1.65 without family history). 
For second BC, the RRs were very high in patients with or 
without family history (4.89 and 3.90, respectively). The larg-
est numbers of familial SPCs were observed for BC (1909), 
followed by colorectal (112), lung (96) and skin (79) cancers.
Cumulative incidence rates for six cancer sites with most 
familial second primary cancer cases including endometrial, 
lung, ovarian, colorectal and skin cancers, and melanoma are 
shown in Figure 1A‐F according to age at diagnosis of SPCs. 
Shown are plots for SPCs with a family history of concordant 
cancer (orange curves) and without a family history (blue 
curves). For the cancers listed, the cumulative incidence with 
a family history was higher than that without family history at 
each age. A large difference between the cumulative incidence 
of SPCs with and without family history was observed for 
ovarian cancer; at the age of 75 years, the cumulative incidence 
with a family history reached 6%, in contrast to 1% when lack-
ing a family history. The incidence rate of the corresponding 
second cancer at the specific age group is shown in Figure S1.
Table 3 shows the cause of death in BC patients with or 
without SPCs according to follow‐up time from diagnosis 
of BC. Among patients with SPCs, BC (mostly including 
second BC) and SPC were the dominant causes of death 
through the follow‐up periods. Deaths due to non‐BC SPCs 
accounted for 34.3% of all deaths, but adding BC patients 
with second BC (30.6%),combined SPC accounted for 
64.9% of all deaths. The proportion of deaths due to sec-
ond BC decreased from 42.6% in the first year of diagnosis 
T A B L E  1  Demography of the breast cancer population followed during the period of 1958‐2015
No. of females followed 4 216 676
Number of cases
A. No. of BC diagnoses 87 752
B. No. of SPC diagnoses in BC patients 14 952 (17.0% of all BC survivors, B/A)
C. Familial SPC 10 280 (68.8% of all BC survivors with SPC, C/B)
D. Familial SPC (concordant) 2228 (21.6% of all familial SPC, D/C)
E. Familial SPC (discordant) 8052 (77.4% of all familial SPC, D/C)
F. No. of third primary cancer diagnoses 2543 (17% of all BC survivors with SPC, F/B)
Number of deaths
G. Deaths among all BC patients 18 998 (21.6% of all BC patients, G/A)
H. Deaths among BC patients with SPC 4828 (32.3% of all diagnosed with SPC, H/B)
I. Deaths among SPC patients with positive family 
history
3356 (32.6% of all familial SPC diagnoses, I/C)
J. Deaths among SPC patients with negative family 
history
1472 (31.5% of all SPC patients with negative family history, J/(B‐C))
K. Deaths among BC patients without SPC 14 170 (16.1% of all BC survivors without SPC, K/(A‐B))
BC, breast cancer; SPC, second primary cancer.
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T A B L E  2  Familial risk for second primary cancers among breast cancer patients




Negative family history Positive family history
N RR 95%CI N RR 95%CI
UAT 138 1.38 1.16‐1.64 5 2.31 0.96‐5.56 0.17
Esophagus 44 1.56 1.15‐2.11 0 ‐ ‐ ‐
Stomach 93 1.37 1.11‐1.69 8 3.14 1.57‐6.28 0.003
Small intestine 46 1.54 1.14‐2.07 0 ‐ ‐ ‐
Colorectum 683 1.17 1.08‐1.26 112a 1.50 1.25‐1.81 <0.001
Colon 499 1.16 1.06‐1.27 45 1.35 1.01‐1.81 <0.001
Rectum 233 1.15 1.01‐1.32 18 1.90 1.19‐3.01 <0.001
Anus 37 1.38 0.99‐1.92 0 ‐ ‐ ‐
Liver 139 1.25 1.06‐1.49 7 2.54 1.21‐5.32 0.007
Pancreas 176 1.20 1.03‐1.39 9 2.35 1.22‐4.52 0.02
Nose 9 1.29 0.66‐2.51 0 ‐ ‐ ‐
Lung 744 1.54 1.43‐1.66 96 2.93 2.40‐3.58 <0.001
Breast 6744 3.90 3.80‐4.00 1909b 4.89 4.67‐5.12 <0.001
Cervix 95 1.07 0.87‐1.31 2 1.58 0.39‐6.32 0.16
Endometrium 627 1.42 1.31‐1.54 37 3.32 2.40‐4.58 <0.001
Uterus 1 2.38 0.32‐17.49 0 ‐ ‐ ‐
Ovary 364 1.49 1.34‐1.65 35 6.28 4.50‐8.75 <0.001
Other female 
genitals
53 1.09 0.83‐1.44 0 ‐ ‐ ‐
Kidney 180 1.44 1.24‐1.68 7 2.12 1.01‐4.44 0.24
Bladder 189 1.30 1.12‐1.51 14 2.21 1.31‐3.74 0.005
Melanoma 423 1.32 1.19‐1.45 26 1.97 1.34‐2.89 <0.001
Skin (SCC) 339 1.35 1.21‐1.51 79c 3.47 2.78‐4.33 <0.001
Eye 25 1.42 0.95‐2.12 0
Nervous system 204 1.01 0.88‐1.17 6 1.16 0.52‐2.57 0.10
Thyroid gland 90 1.72 1.39‐2.12 1 2.73 0.38‐19.42 0.31
Endocrine gland 172 1.17 1.01‐1.37 8 3.50 1.75‐6.99 0.004
Bone 10 1.83 0.96‐3.48 0 ‐ ‐ ‐
Connective tissue 66 2.15 1.67‐2.76 0 ‐ ‐ ‐
Non‐Hodgkin 
lymphoma
224 1.21 1.05‐1.38 10 2.03 1.09‐3.77 0.01
Hodgkin 
lymphoma
15 1.29 0.77‐2.17 0 ‐ ‐ ‐
Myeloma 79 1.06 0.85‐1.33 2 2.08 0.52‐8.31 0.15
Leukemia 222 1.38 1.20‐1.57 5 1.32 0.55‐3.17 0.18
CUP 253 1.37 1.21‐1.55 10 1.82 0.98‐3.38 0.01
All cancersd 4672 3.00 2.91‐3.09 10280 3.54 3.46‐3.62 <0.001
All cancerse 1905 1.25 1.19‐1.31 4394 1.53 1.49‐1.58 <0.001
For specific cancer as SPC, the reference group is the general population in the database had neither a family history of SPC nor BC (except for risk estimation of second 
BC), which is used to calculate the incidence of this specific cancer as first primary cancer.
UAT, upper aerodigestive tract; SCC, squamous cell carcinoma; CUP, cancer of unknown primary.
Bolding, italic and underlining indicate that the 95%CI, 99%CI and 99.9%CI did not overlap with 1.00 respectively.
a12 of the 112 cases had only family history of in situ colorectal cancer. 
b100 of the 1909 cases had only family history of in situ BC. 
c41 of the 79 cases had only family history of in situ skin cancer. 
dBreast cancer is included into all cancers. 
eBreast cancer is excluded from all cancers. 
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of BC to 23.2% after 10 years of diagnosis. The propor-
tion of patients, who died of non‐breast SPCs was stable at 
around 30%‐35%. In the first year after BC diagnosis, 2.1% 
patients died of higher order primary cancer and in the lon-
gest follow‐up time the proportion increased to 7.6%. For 
women diagnosed only with BC, the major cause of death 
F I G U R E  1  Cumulative incidence of second primary cancers (SPCs) according to family history and age at diagnosis of SPCs among breast 
cancer patients. Figures from A to F are respectively for endometrial, lung, ovarian and colorectal cancers, melanoma and skin cancers (SCC). SPC, 
second primary cancer. FH positive/negative, BC patients with/without a family history of specific cancer (for example, endometrial cancer in (A) 
in first‐degree relatives
T A B L E  3  Cause of death in breast cancer patients with or without second primary cancer according to follow‐up time from breast cancer 
diagnosis
Breast cancer Cause of death
<1 y (N, % 
in column)
1‐4 y (N, % 
in column)
5‐10 y (N, % 
in column)
>10 y (N, % 
in column)
All (N, % in 
column)
With SPC Breast cancer a 11 (7.7) 86 (10.1) 138 (9.2) 211 (9.1) 466 (9.6)
b 61 (42.6) 344 (40.4) 533 (35.4) 540 (23.2) 1478 (30.6)
SPC 40 (30.0) 258 (30.3) 543 (36.0) 815 (35.0) 1656 (34.3)
Higher order primary cancer 3 (2.1) 26 (3.0) 56 (3.7) 177 (7.6) 262 (5.4)
Other cancers 11 (7.7) 54 (6.3) 100 (6.6) 252 (10.8) 417 (8.6)
Other causes 17 (11.9) 83 (9.8) 136 (9.0) 333 (14.3) 569 (11.8)
All (N, % in row) 143 (3.0) 851 (17.6) 1506 (31.2) 2328 (48.2) 4828 (100.0)
Without SPC Breast cancer 817 (77.0) 4032 (86.2) 4006 (81.1) 2190 (62.7) 11045 (77.9)
Other cancers 48 (4.5) 104 (2.2) 152 (3.1) 184 (5.3) 488 (3.4)
Other causes 196 (18.5) 541 (11.6) 779 (15.8) 1121 (32.1) 2637 (18.6)
All (N, % in row) 1061 (7.5) 4677 (33.0) 4937 (34.8) 3495 (24.7) 14170 (100.0)
SPC, second primary cancer.
Higher order primary cancer, 3rd, 4th or 5th primary cancer.
a, Breast cancer patients diagnosed with non‐breast second primary cancer and dying of breast cancer; b, Breast cancer patients diagnosed with second breast cancer and 
dying of breast.
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was BC throughout the follow‐up time and other causes ac-
counted for around 15% but increased to 32.1% of all death 
cases in the follow‐up time after 10 years.
Table S1 shows the same data as Table 3 but covers only 
the follow‐up period from 2001 to 2015. Among patients 
with second BC diagnoses the overall proportions of deaths 
due to BC decreased from 30.6% in Table 3 to 28.1% in Table 
S1. A concomitant increase was observed in deaths due to 
non‐BC cancers (from 34.3% to 38.5%).
Figure 2 displays the distribution of the cause of death in pa-
tients with SPCs when SPC conferred at least 50 deaths. Second 
pancreatic, lung, liver, breast, stomach and ovarian cancers each 
accounted for more than 70% of the deaths in patients with the 
corresponding SPC, while skin and endometrial cancers and 
CUP appeared least fatal. The relative contributions of deaths 
were reversed for deaths due to BC and other causes which were 
highest for the least fatal SPCs. Other cancers were a minor 
cause of death, except for CUP for which half of the deaths were 
due to other causes. Details of the distribution of the cause of 
deaths for all SPCs are shown in Table S2.
4 |  DISCUSSION
The proportion of BC patients diagnosed with SPCs was 
17.0%, which interestingly exactly matched the proportion 
for third primary cancers among SPCs. Second BC was the 
main SPCs, accounting for more than half of the cases with 
SPCs. The median follow‐up time from diagnosis of first BC 
to second BC was much shorter than to the non‐breast SPCs 
and many BCs were diagnosed synchronously. In patients 
diagnosed with SPCs, the main cause of death was SPCs 
(64.9%), among which close to half of were second BCs. For 
the patients without SPCs, BC accounted for most deaths 
(77.9%).
Risk of SPCs in BC patients has been the subject of many 
studies, and second endometrial, ovarian, stomach and colon 
cancers, and melanoma were reported to occur most fre-
quently according to a review.20 Apart from these cancers, 
increased risks of more SPCs were found in the current study, 
and importantly, family history contributed to the risk for the 
SPCs. Risk of second BC was very high irrespective of fam-
ily history, indicating that most BC patients had a greater risk 
of developing second BC than other SPC. A family history of 
ovarian cancer in BC patients was associated with more than 
a 4 fold risk of second ovarian cancer, liver and endocrine 
gland cancers a 3 fold risk, skin (SCC) cancer a 2.5 fold risk, 
endometrial cancer more than a 2 fold risk, pancreatic and 
lung cancers close to a 2 fold risk cancer, and rectal, kid-
ney, bladder cancers, melanoma and non‐Hodgkin lymphoma 
around a 1.5 fold risk. The increased risks for familial SPCs 
may be a consequence of complex genetic and environmental 
F I G U R E  2  Distribution of cause of death: second primary cancer, breast cancer, higher order primary cancer, other cancers and other causes 
among breast cancer patients with second primary cancer. Only cancer sites with more than 50 death cases are displayed
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factors, including reproductive and other behavioral factors. 
Mutations in genes such as BRCA1/2 are likely to contribute 
to the high familial risk of second breast and ovarian can-
cers,21,22 as well as the risk of pancreatic cancer and mela-
noma.23 Hormonal level and reproductive factors may also 
contribute to the increased familial risk of breast, ovarian 
and endometrial cancers. Smoking is probably related to the 
increased familial risk of second lung, bladder and kidney 
cancers, and alcohol consumption to liver cancer.
The fatality rate in patients with SPC (32.3%) was twice 
as high as in patients without SPC (16.1%). This is possibly 
due to worse survival in most cancers other than BC, which 
was illustrated by high fatality rate in second stomach, pan-
creatic and liver cancers and CUP (Figure 2). For cancers 
with relatively good survival, such as melanoma, endometrial 
and skin cancers when diagnosed as SPC, the leading cause 
of death was BC. However, the fatality rate in patients with 
SPCs was not dependent on the family history of cancer, con-
sistent with the literature reporting that family history does 
not impact fatality rate of BC patients.24,25
It is important to consider some quality parameters in the 
context of the present data. SPCs undergo the same rigorous 
histological diagnostics as are applied for first cancers in 
the Swedish cancer registration system which is mandated 
to request separate and consistent tumor notifications from 
clinicians and pathologist. Accordingly an ad hoc study on 
the diagnostic accuracy of second neoplasms in the Swedish 
Cancer Registry found 98% to be correctly classified; no 
recorded SPC was found to be a metastasis.26 However, tu-
mors in the same organs are more problematic as the distinc-
tion between a novel neoplasia and a recurrence is subject 
to tumor histology and anatomical location; in paired organs 
contralateral presentation, such as in BC, may favor call-
ing of two separate tumors.17 Cause of death registration is 
done by the registrar using the relevant information regard-
ing circumstances around the deaths. One study performed 
in Sweden, based on international standards, indicated 77% 
agreement between the cause of death from death certifi-
cates and the cause of death expected based on case summa-
ries, and highest agreement was with malignant neoplasms 
as the underlying cause of death.27 A contributing factor 
to the accuracy of death certificates on cancer patients in 
Sweden is that 85% of patients die in hospitals and for more 
than 90% of cancer deaths the related hospital journals have 
been the base for issuing the death certificate.28,29 Some 
clinical and behavioral factors are not available in the da-
tabase, such as hormone receptor status, treatment for the 
BC, smoking and physical activity. However we adjusted 
socioeconomic status, which can reduce the confounding to 
some extent.
In conclusion, 17% of BC patients were diagnosed with 
SPCs in our database, among which 68.8% were familial. 
For BC patients with family members diagnosed with cancer, 
18.3% of non‐breast SPCs were attributed to family history. 
High familial risks were found in cancers that share genetic, 
reproductive or behavioral factors with BC. SPC was the 
leading cause of death in the patients diagnosed with SPCs. 
Our results suggest that family history gives guidance on po-
tential risk of SPCs and it may help counseling about risk fac-
tors and early detection of SPC in BC survivors. The impact 
of family history on SPCs was remarkably high which con-
tributed to the overall high death rate by SPCs. Any attempts 
to increase survival in BC needs to counter the challenge of 
SPCs.
CONFLICT OF INTEREST
AH is shareholder in Targovax ASA. AH is employee and 
shareholder in TILT Biotherapeutics Ltd. Other authors de-
clared no conflict of interest.
ORCID
Guoqiao Zheng  https://orcid.org/0000-0003-4337-9017 
Akseli Hemminki  https://orcid.org/0000-0001-7103-8530 
Kari Hemminki  https://orcid.org/0000-0002-2769-3316 
REFERENCES
 1. Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. 
Aetiology, genetics and prevention of secondary neoplasms in 
adult cancer survivors. Nat Rev Clin Oncol. 2013;10:289‐301.
 2. Vogt A, Schmid S, Heinimann K, et al. Multiple primary tu-
mours: challenges and approaches, a review. ESMO Open. 
2017;2:e000172.
 3. Chen T, Fallah M, Jansen L, et al. Distribution and risk of the 
second discordant primary cancers combined after a specific first 
primary cancer in German and Swedish cancer registries. Cancer 
Lett. 2015;369:152‐166.
 4. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. 
Second malignant neoplasms: assessment and strategies for risk 
reduction. J Clin Oncol. 2012;30:3734‐3745.
 5. Hemminki K, Ji J, Forsti A. Risks for familial and contralateral 
breast cancer interact multiplicatively and cause a high risk. 
Cancer Res. 2007;67:868‐870.
 6. Palomaki GE. Is it time for BRCA1/2 mutation screening in the 
general adult population?: impact of population characteristics. 
Genet Med. 2015;17:24‐26.
 7. Yurgelun MB, Hiller E, Garber JE. Population‐wide screening 
for germline BRCA1 and BRCA2 mutations: too much of a good 
thing? J Clin Oncol. 2015;33:3092‐3095.
 8. Chen T, Fallah M, Kharazmi E, Ji J, Sundquist K, Hemminki K. 
Effect of a detailed family history of melanoma on risk for other 
tumors: a cohort study based on the nationwide Swedish Family‐
Cancer Database. J Invest Dermatol. 2014;134:930‐936.
 9. Chen T, Hemminki K, Kharazmi E, Ji J, Sundquist K, Fallah 
M. Multiple primary (even in situ) melanomas in a patient pose 
significant risk to family members. Eur J Cancer. 2014;50: 
2659‐2667.
   | 407ZHENG Et al.
 10. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second 
Cancer Risk Up to 40 Years after Treatment for Hodgkin's 
Lymphoma. N Engl J Med. 2015;373:2499‐2511.
 11. Donin N, Filson C, Drakaki A, et al. Risk of second primary 
malignancies among cancer survivors in the United States, 1992 
through 2008. Cancer. 2016;122:3075‐3086.
 12. Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. 
Death causes in breast cancer patients. Ann Oncol. 2012;23:604‐610.
 13. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death 
among cancer patients. Ann Oncol. 2017;28:400‐407.
 14. Lorenzo Bermejo J, Hemminki K. Familial risk of cancer shortly 
after diagnosis of the first familial tumor. J Natl Cancer Inst. 
2005;97:1575‐1579.
 15. Brooke HL, Talback M, Hornblad J, et al. The Swedish cause of 
death register. Eur J Epidemiol. 2017;32:765‐773.
 16. Ji J, Sundquist K, Sundquist J, Hemminki K. Comparability of 
cancer identification among Death Registry, Cancer Registry and 
Hospital Discharge Registry. Int J Cancer. 2012;131:2085‐2093.
 17. Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic 
Cancer Registries ‐ an overview of their procedures and data com-
parability. Acta Oncol. 2017;1–16.
 18. Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and 
survival in lung cancer. Lung Cancer. 2014;86:78‐84.
 19. Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns 
of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.
 20. Molina‐Montes E, Requena M, Sánchez‐Cantalejo E, et al. 
Risk of second cancers cancer after a first primary breast can-
cer: a systematic review and meta‐analysis. Gynecol Oncol. 
2015;136:158‐171.
 21. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovar-
ian cancer after breast cancer in BRCA1 and BRCA2 carriers. 
Gynecol Oncol. 2005;96:222‐226.
 22. Rhiem K, Engel C, Graeser M, et al. The risk of contralateral 
breast cancer in patients from BRCA1/2 negative high risk 
families as compared to patients from BRCA1 or BRCA2 pos-
itive families: a retrospective cohort study. Breast Cancer Res. 
2012;14:R156.
 23. Moran A, O’Hara C, Khan S, et al. Risk of cancer other than 
breast or ovarian in individuals with BRCA1 and BRCA2 muta-
tions. Fam Cancer. 2012;11:235‐242.
 24. Chang ET, Milne RL, Phillips K‐A, et al. Family history of breast 
cancer and all‐cause mortality after breast cancer diagnosis in 
the Breast Cancer Family Registry. Breast Cancer Res Treat. 
2009;117:167‐176.
 25. Melvin JC, Wulaningsih W, Hana Z, et al. Family history of breast 
cancer and its association with disease severity and mortality. 
Cancer Med.. 2016;5:942‐949.
 26. Frödin J‐E, Ericsson J, Barlow L. Multiple primary malignant tu-
mors in a national cancer registry. Reliability of reporting. Acta 
Oncol. 1997;36:465‐469.
 27. Johansson LA, Björkenstam C, Westerling R. Unexplained dif-
ferences between hospital and mortality data indicated mistakes 
in death certification: an investigation of 1,094 deaths in Sweden 
during 1995. J Clin Epidemiol. 2009;62:1202‐1209.
 28. Cohen J, Bilsen J, Addington‐Hall J, et al. Population‐based 
study of dying in hospital in six European countries. Palliat Med. 
2008;22:702‐710.
 29. Socialstyrelsen. Causes of death 2010. Stockholm: National 
Board of Health and Welfare; 2011:258.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.  
How to cite this article: Zheng G, Hemminki A, 
Försti A, Sundquist J, Sundquist K, Hemminki K. 
Second primary cancer after female breast cancer: 
Familial risks and cause of death. Cancer Med. 
2019;8:400–407. https://doi.org/10.1002/cam4.1899
